Kalaris Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

Kalaris Therapeutics

05/08/2025 15:53

Kalaris Therapeutics Inc KLRS.OQ KLRS.O is expected to  show no change in quarterly revenue when it reports  results on August 7 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Kalaris Therapeutics Inc is for a loss of 52 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 33.8% in the last three months. ​

Wall Street's median 12-month price target for Kalaris Therapeutics Inc is $11.50, about 77.6% above its last closing price of $2.58

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.75
-0.77
-2.52
Missed
-225.2
2025
​
Jun. 30 2024
-1.61
-2.41
-1.15
Beat
52.4
​​Mar. 31 2024
-3.81
-3.60
-5.98
Missed
-66
Dec. 31 2023
-10.66
-9.84
-8.28
Beat
15.9​
Sep. 30 2023
-9.40
-9.57
-8.97
Beat
6.3
Jun. 30 2023
-9.92
-10.35
-11.04
Missed
-6.7

This summary was machine generated August 5 at 14:53 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)